Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × liposomal doxorubicin × Sarcoma × Clear all

Phase

Phase 2 6 Phase 1 6 Phase 1/2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5 Sarcoma 1 Gastrointestinal 1

Conditions

Interventions

Doxorubicin 7 Radiotherapy 4 Radiation 3 Magnetic Resonance Spectroscopy 3 Ifosfamide 3 regorafenib 2 Temozolomide 2 Surgical Procedures, Operative 2 Methotrexate 2 Imatinib Mesylate 2 Etoposide 2 Drug Therapy 2 Cyclophosphamide 2 Cisplatin 2 veliparib 1 selinexor 1 pirarubicin 1 pazopanib 1 niraparib 1 merphos 1 liposomal doxorubicin 1 fludarabine phosphate 1 dostarlimab 1 cabozantinib 1 brigimadlin 1 apatinib 1 anlotinib 1 Zoledronic Acid 1 X-Rays 1 Whole-Body Irradiation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03342300 2020-05-19

PDVPSTS

Peking University People's Hospital

Phase 2/3 Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡